Modified human immunodeficiency virus anti-fusogenic GP41 peptides comprising a maleimide-containing group
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Oct 27, 2009
Grant Date -
Mar 31, 2005
app pub date -
Sep 24, 2004
filing date -
May 17, 1999
priority date (Note) -
Expired
status (Latency Note)
Importance
Abstract
Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully